Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients
2017; Elsevier BV; Volume: 5; Issue: 6 Linguagem: Inglês
10.1016/j.jaip.2017.08.035
ISSN2213-2201
AutoresZahava Vadasz, Yuval Tal, Menachem Rotem, Vered Shichter-Confino, Keren Mahlab‐Guri, Yael Graif, Aharon Kessel, Nancy Agmon‐Levin, Ramit Maoz‐Segal, Shmuel Kivity, Shira Benor, Idit Lachover‐Roth, Yuri Zeldin, Migel Stein, Ori Toker, Gamal Hassoun, Shira Bezalel‐Rosenberg, Elias Toubi, Ilan Asher, Zev Sthoeger,
Tópico(s)Coagulation, Bradykinin, Polyphosphates, and Angioedema
ResumoChronic spontaneous urticaria (CSU) is a debilitating disorder. Thus, well-defined therapeutic strategies are required to achieve a maximal remission and maintain quality of life. Half of all patients with severe CSU require high doses of antihistamines coupled with short courses of steroids.1 Cyclosporine A (CsA) is well established for its beneficial effect. However, frequent side effects and the fear of malignancies in long-term users required the development of better and safer therapeutic options.
Referência(s)